hydroxychloroquine has been researched along with Lymphangiomyomatosis in 3 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM)." | 9.27 | Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. ( Bagwe, S; Cui, Y; El-Chemaly, S; Goldberg, HJ; Henske, EP; Lamattina, AM; Moss, J; Rosas, IO; Taveira-Dasilva, A, 2018) |
| "We have previously conducted the Sirolimus and Autophagy Inhibition in LAM (SAIL) trial, a phase 1 dose-escalation study of the combination of sirolimus and hydroxychloroquine in patients with lymphangioleiomyomatosis (LAM)." | 5.27 | Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. ( Bagwe, S; Cui, Y; El-Chemaly, S; Goldberg, HJ; Henske, EP; Lamattina, AM; Moss, J; Rosas, IO; Taveira-Dasilva, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Luo, M | 1 |
| Xiang, B | 1 |
| Chen, S | 1 |
| Ji, Y | 1 |
| Lamattina, AM | 1 |
| Taveira-Dasilva, A | 2 |
| Goldberg, HJ | 2 |
| Bagwe, S | 2 |
| Cui, Y | 2 |
| Rosas, IO | 2 |
| Moss, J | 2 |
| Henske, EP | 2 |
| El-Chemaly, S | 2 |
| Peters, E | 1 |
| Haughey, M | 1 |
| Bienfang, D | 1 |
| Jones, AM | 1 |
| Julien-Williams, P | 1 |
| Villalba, JA | 1 |
| Maurer, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus[NCT01687179] | Phase 1 | 14 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Primary endpoint of this study was safety. Safety was assessed based on the adverse events and serious adverse events that occurred in these patients when they were on this combination therapy. Percentage of adverse events in each system at a dose was calculated from the total adverse events at that dose. Subjects were closely monitored and adverse events were classified and graded according to the Common Terminology Criteria for Adverse Events, (CTCAE) Version 4.0." (NCT01687179)
Timeframe: 48 weeks
| Intervention | Percentage of adverse events (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac Disorders | Eye Disorders | GI Disorders | General Disorders, Administration site condistions | Immune System disorders | Infections and infestations | Injury, poisoning, procedural complications | Investigations | Metabolism and nutrition disorders | Musculoskeletal, connective tissue disorders | Nervous system disorders | Psychiatric disorders | Renal and urinary disorders | Reproductive system and breast disorder | Respiratory, thoracic, mediastinal disorders | Skin and Subcutaneous disorders | Vascular disorders | |
| Sirolimus and Hydroxychloroquine 200 mg | 2.27 | 0 | 18.18 | 18.18 | 0 | 15.91 | 0 | 6.82 | 0 | 0 | 4.55 | 0 | 0 | 6.82 | 2.27 | 25.0 | 0 |
| Sirolimus and Hydroxychloroquine 400 mg | 1.11 | 1.11 | 22.22 | 6.67 | 0.56 | 8.33 | 0.56 | 20 | 3.33 | 4.44 | 5.00 | 0.56 | 7.78 | 1.11 | 9.44 | 6.11 | 1.67 |
1 review available for hydroxychloroquine and Lymphangiomyomatosis
| Article | Year |
|---|---|
The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combinat | 2020 |
2 trials available for hydroxychloroquine and Lymphangiomyomatosis
| Article | Year |
|---|---|
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
Topics: Acetyl-CoA Carboxylase; Adult; Biomarkers; Correlation of Data; Drug Monitoring; Drug Therapy, Combi | 2018 |
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
Topics: Adult; Aged; Autophagy; Diarrhea; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Forc | 2017 |